Intraperitoneal cisplatin and regional hyperthermia for ovarian carcinoma.
OBJECTIVE
To review the theoretical basis and results of a Phase I study of concurrent intraperitoneal cisplatin and hyperthermia in the treatment of ovarian carcinoma.


METHODS
Previously treated patients with epithelial ovarian carcinoma received intraperitoneal instillation of cisplatin and 60 minutes of regional hyperthermia, with a goal temperature of 41.5 degrees C. Cisplatin dose started at 20 mg/m2 with escalation to the maximally tolerated dose. Six such cycles given every 3 weeks were planned. Pharmacokinetic studies with and without hyperthermia were performed.


RESULTS
Fifteen patients receiving 17 courses of treatment were evaluable. The maximally tolerated dose of cisplatin was between 80 and 120 mg/m2. The dose limiting toxicity was nephrotoxicity in all but one course. The median intraperitoneal temperature was 40.7 degrees C; the majority of treatments in which the goal temperature was not reached had power limited by patient discomfort. No major toxicities attributable to hyperthermia were noted. Pharmacokinetic studies noted no significant differences between treatments with vs. without hyperthermia, with intraperitoneal to plasma area under the curve ratios being 30-35. Ten patients had a decline in their CA-125 count during treatment, although in only two patients did this response persist beyond their course of treatment.


CONCLUSIONS
Intraperitoneal cisplatin and regional hyperthermia can be performed with reasonable toxicity. The maximally tolerated dose of 80-120 mg/m2 in pretreated patients (which is similar to those reported with cisplatin alone) and median intraperitoneal temperatures of 40.7 degrees C, however, are felt to be too low to be efficacious in a significant percentage of women with bulky recurrent disease. Further study using intravenous thiosulfate and controlled analgesia is being performed.
Leopold
K A
KA
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710.
Oleson
J R
JR
Clarke-Pearson
D
D
Soper
J
J
Berchuck
A
A
Samulski
T V
TV
Page
R L
RL
Blivin
J
J
Tomberlin
J K
JK
Dewhirst
M W
MW
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood; D002945:Cisplatin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D005260:Female; D006207:Half-Life; D006801:Humans; D006979:Hyperthermia, Induced / Q000009:adverse effects; D007263:Infusions, Parenteral; D008657:Metabolic Clearance Rate; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000628:therapy*; D010529:Peritoneal Cavity
D015295:Antigens, Tumor-Associated, Carbohydrate; D002945:Cisplatin